AGP Executive Report
Last update: 9 hours agoRare Disease Research: Dutch and US teams used patient-derived “mini brain” models to map the DHDDS mechanism and report that nicotinamide mononucleotide (NMN, a vitamin B3 form) may slow progression of a devastating childhood neurodegenerative disorder. Clinical Trials & Neurology: Multiple studies highlight new options for immune-mediated nerve conditions, including efgartigimod in CIDP and comparisons of IVIg versus plasma exchange in Guillain-Barré syndrome. Biotech Partnerships (Netherlands): Intravacc (NL) and SynphaBase (CH) announced a strategic partnership to streamline conjugate vaccine development, from synthetic oligosaccharides to conjugation and GMP manufacturing. Healthcare Innovation (Netherlands): Azafaros (NL) will present Phase 3 progress on nizubaglustat for lysosomal storage disorders with neurological involvement at BIO 2026 in San Diego. Public Health & Care Access: A new Scottish MSP story spotlights how hospital education support helps families with seriously ill children—an angle that resonates with Dutch readers following debates on care continuity.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
